Last reviewed · How we verify
MK-0653, ezetimibe
Ezetimibe inhibits the absorption of cholesterol in the small intestine.
Ezetimibe inhibits the absorption of cholesterol in the small intestine. Used for Hyperlipidemia, Homozygous familial hypercholesterolemia.
At a glance
| Generic name | MK-0653, ezetimibe |
|---|---|
| Sponsor | Organon and Co |
| Drug class | cholesterol absorption inhibitor |
| Target | NPC1L1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ezetimibe works by binding to the Niemann-Pick C1-Like 1 (NPC1L1) protein on the surface of intestinal cells, preventing the absorption of cholesterol from the diet. This leads to a decrease in the amount of cholesterol available for transport to the liver, resulting in lower levels of cholesterol in the blood.
Approved indications
- Hyperlipidemia
- Homozygous familial hypercholesterolemia
Common side effects
- Musculoskeletal pain
- Diarrhea
- Flatulence
Key clinical trials
- Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036) (PHASE3)
- Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia (0653-141)(COMPLETED) (PHASE4)
- MD Ezetimibe Cyclosporine Interaction (0653-057) (PHASE1)
- Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040) (PHASE3)
- Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED) (PHASE4)
- Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150) (PHASE4)
- Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED) (PHASE3)
- A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |